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Immune cells not only affect tissue homeostasis at the site of inflammation but also exert 
systemic effects contributing to multiple chronic conditions. Recent evidence clearly 
supports an altered T helper 17/regulatory T  cell (Th17/Treg) balance leading to the 
development and progression of inflammatory diseases that not only affect the gastro-
intestinal tract but also have whole-body manifestations, including insulin resistance. 
Epigenetic mechanisms are amenable to both environmental and circulating factors and 
contribute to determining the T cell landscape. The recently identified participation of 
the gut microbiota in the remodeling of the epigenome of immune cells has triggered 
a paradigm shift in our understanding of the etiology of various inflammatory diseases 
and opened new paths toward therapeutic strategies. In this review, we provide an over-
view of the contribution of the Th17/Treg balance in the development and progression 
of inflammatory  bowel diseases and metabolic diseases. We discuss the involvement 
of epigenetic mechanisms in the regulation of T cell function in the particular context of 
dysbiosis. Finally, we examine the potential for nutritional interventions affecting the gut 
microbiota to reshape the T cell epigenome and address the inflammatory component 
of various diseases.
Keywords: gut microbiota, epigenetics, regulatory T cell, T helper 17 cell, inflammatory bowel diseases, obesity, 
type 2 diabetes
iNTRODUCTiON
Immune homeostasis is a complex process involving a wide variety of key immunological players. 
Failure to establish a balanced immune response contributes to an ever-growing list of chronic 
diseases. Over the last few decades, the involvement of T helper 17 (Th17) cells and regulatory 
T cells (Tregs) in the maintenance of immune homeostasis has received increasing attention. It is 
now widely accepted that an altered Th17/Treg balance is associated with a wide variety of inflam-
matory diseases [Figure 1; (1–7)]. Given the role of epigenetic mechanisms in the regulation of 
immune functions, notably in the control of Th17 cell and Treg differentiation, it is not surprising 
that inflammatory diseases are linked to a substantial remodeling of the host epigenome in various 
FiGURe 1 | T helper 17 (Th17) and regulatory T cell (Treg) lineage determination and the Th17/Treg balance in health and diseases.  
(A) The differentiation of naïve T-cells into different lineages is regulated by specific cytokines. TGF-β in combination with IL-2 induces the expression of the 
transcription factor Foxp3 and Treg differentiation, which are characterized by the secretion of TGF-β, IL-10, and IL-33. TGF-β combined with IL-6 leads to the 
differentiation into Th17, which is characterized by the transcription factor Rorc (or RORγt). This process is amplified under the influence of IL-21 and both IL-1β  
and IL-23 have been reported to potentially contributing to Th17 differentiation. Th17 can secrete different cytokines, including IL-17A, IL-17F, IL-21, IL-22, IL-23, 
and IL-25. The differentiation into Treg or Th17 is a tightly controlled process regulated, at least partly, by epigenetic mechanisms. In naïve T-cell, the T-bet (or Tbx1) 
locus is characterized by both H3K4me3 (a permissive histone mark) and H3k27me3 (a repressive histone mark), whereas the Rorc, interferon gamma (Ifng), Foxp3, 
and Il17a loci show a total absence of such marks, making those five loci susceptible to both repression or expression of these genes. All five genes are 
hypermethylated in naïve T-cell contributing to gene silencing. Tregs show H3K4me3 on Foxp3 and H3K27me3 on Il17a, supporting the expression of Foxp3 while 
silencing Il17a. The demethylation of Foxp3 and the hypermethylation of Rorc further contribute to Foxp3 expression. In the same cells, T-bet and Rorc are marked 
by both histone modifications, whereas Ifng is devoid of these, rendering these loci more unstable. Th17 cells show H3K27me3 on Ifng and H3K4me3 on Rorc, 
Il17a, Il17f, Il21, and Il23, facilitating the expression of Rorc and supporting the secretion of the signature cytokines by these cells. This process is further supported 
by the hypermethylation observed in the Ifng and Foxp3 loci, whereas the Il17a, T-bet, and Rorc are characterized by a demethylation, supporting gene expression. 
microRNAs can also contribute to the differentiation and function of Th17, and both miR-155 and miR-326 contribute to the production of IL-17A. TGF-β, 
transforming growth factor-beta; IL-2, interleukin-2; Foxp3, forkhead box P3; Rorc (or RORγt), retinoic acid receptor-related orphan receptor; T-bet, T-box1; 
H3K4me3, trimethylation of histone H3 on lysine 4 (green dot); H3K4me27, trimethylation of histone H3 on lysine 27 (red dot); IFN-γ, interferon gamma. (B) An 
imbalance between the number and activity of Th17 and Treg has been linked to several diseases. The predominance of Th17 is associated with inflammatory bowel 
diseases, obesity, and some allergic conditions, whereas Tregs have been linked to different forms of arthritis as well  
as several types of infections.
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tissues [Figure 1; (8–10)]. There is growing evidence that the gut 
microbial community is critical for the maintenance of a healthy 
host, and clear links between the gut microbiota and the central 
nervous system, or the cardiovascular and metabolic functions 
have been established (11–14). Consequently, perturbations of 
the gut microbiota (or dysbiosis), encompassing reduced micro-
bial diversity and changes in microbiota composition, have been 
associated with a large number of chronic conditions (15). The 
vast majority of diseases that develop in the face of dysbiosis are 
characterized by immune alterations, and in particular chronic 
inflammation, which affect not only the gastrointestinal (GI) 
tract but also spread to the systemic circulation and central or 
peripheral tissues (16, 17). Some of the key manifestations of 
these inflammatory conditions, that include inflammatory bowel 
disease (IBD) and metabolic diseases, involve modulation of the 
local and circulating cytokine profile, but also significant changes 
in the frequency, function, and trafficking pattern of immune 
cells, including major alterations in the Th17/Treg balance, 
affecting the “immunological environment” in the host tissues 
(18–20). How dysbiosis orchestrates the remodeling of the T-cell 
landscape and whether this could involve epigenetic mechanisms 
still remain unclear. Perhaps an even more important question 
that remains unanswered is whether the gut microbiota could 
be manipulated to reshape the T-cell epigenome in the context 
of inflammatory diseases providing novel strategies to limit the 
pandemic of IBD and metabolic diseases. Although further work 
is still needed to provide definitive answers to those questions, 
recent progress in the field has shed light on important mecha-
nisms driving the Th17/Treg balance and that could be targeted 
to treat inflammatory diseases.
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Th17/TReG BALANCe iN iBDs
Th17 cells and Tregs are T-cell subsets that have essential roles 
in various immune processes, including inflammation, as well 
as disease progression. The Th17 lineage mediates effector 
functions and is under the transcriptional regulation of retinoic 
acid-related orphan receptor (ROR) γt (21–23). Th17  cells 
are further characterized by the production of their signature 
cytokines, including interleukin (IL)-17, IL-21, IL-22, IL-23, and 
IL-25, which promote tissue inflammation via the induction of 
other pro-inflammatory cytokines and chemokines [Figure  1; 
(23–25)]. At the other end of the immune regulation spectrum, 
natural Tregs and inducible Tregs differentiate in the thymus 
and periphery, respectively, and play an indispensable role in the 
suppressive control of both innate and adaptive immunity in vivo 
(26, 27). Developmentally, Tregs are regulated by the transcrip-
tion factor forkhead box P3 (Foxp3) and express high levels of 
the IL-2-α chain receptor, CD25. Both Foxp3 and CD25 play 
pivotal roles in Treg differentiation, induction, and stabilization 
of their regulatory phenotype and immunosuppressive func-
tions, including the secretion of IL-10, IL-35, and transforming 
growth factor (TGF)-β [Figure 1; (28–34)]. Tregs can be further 
divided into naturally occurring and peripherally induced Tregs. 
Phenotypically, these Treg cell subsets are indistinguishable from 
each other and utilize similar mechanisms to suppress immune 
responses including (1) cell-to-cell contact, (2) regulation of 
the effects of dendritic cells on effector cells, (3) secretion of 
inhibitory cytokines including IL-10, IL-35, and TGF-β, and 
(4) cytolysis of target cells (35). Interestingly, some studies have 
demonstrated that the development and function of a subset of 
peripherally derived Tregs are independent of Foxp3 expression 
and are characterized by their ability to produce high levels of the 
immunosuppressive IL-10 and TGF-β to suppress both adaptive 
and innate immune responses (36).
Despite these distinct functional differences, Th17 and 
Tregs are linked by their shared requirement for the cytokine 
TGF-β during development (21–23). This represents a close, 
fundamental relationship between the two cell types and further 
suggests shared developmental pathways during the progression 
of immune-mediated inflammatory conditions (22, 37). This 
is supported by data suggesting that the balance of Th17/Treg 
plays a role in the regulation of intestinal inflammation in IBD 
(38–40). A balance between the effector and regulatory functions 
(respectively mediated by Th17  cells and Tregs) is particularly 
important in the GI tract as it represents a critical barrier 
between the internal and external environments. The GI tract 
is under constant challenge from microbial and food antigens, 
which can generate both beneficial and harmful effects; hence, 
the normal intestinal immune system is constantly activated and 
tightly regulated. When this delicate balance between effector and 
regulatory responses is breached, the development of IBD ensues 
(38, 39). IBD are chronic inflammatory diseases of the GI tract, 
with unknown etiology, consisting of two major forms called 
ulcerative colitis (UC) and Crohn’s disease (CD), characterized by 
excessive inflammation of the intestine. The current hypothesis 
regarding the pathophysiology of IBD postulates that inflamma-
tion in these conditions is a result of the interaction of multiple 
factors including the intestinal microbiota, abnormalities of 
mucosal permeability, environmental and genetic factors, and a 
dysregulated host-immune response (41–44). Nonetheless, it still 
remains unclear whether chronic inflammation is responsible for 
the development of dysbiosis in IBD, or if disturbance in the gut 
microbiota is the trigger leading to inflammation in the GI tract. 
Despite the fact that animal models have suggested the possibil-
ity of dysbiosis preceding chronic inflammation (45), similar 
evidence is yet to be clearly demonstrated in human studies.
Changes in Th17 cells and Tregs numbers and functions are 
well established in both patients with IBD and murine colitis 
models. Elevated transcript levels of IL17 have been reported in 
the mucosa of both UC and CD patients compared to healthy 
controls [Table 1; (2, 3)]. The relationship between IL-17 and IBD 
genesis, however, is likely to be complex, given that anti-IL-17 
monoclonal antibody therapy failed to improve outcomes in CD 
(46). Serum levels of IL-22, another Th17-related cytokine, are 
significantly increased in IBD patients, an observation further 
recapitulated in a mouse model of colitis (47, 48). This excessive 
pro-inflammatory response results from a decreased differentia-
tion and accumulation, as well as functional defects in Tregs in the 
inflamed tissues (49) or in peripheral blood of IBD patients with 
active disease (50). The upregulation of these pro-inflammatory 
cytokines is correlated with a significant reduction in the levels 
of several immunosuppressive cytokines including TGF-β, IL-10, 
and IL-33 (41, 49). All these events favor the establishment of a 
local effector immune response, leading to a disturbed intestinal 
immune system, resulting in chronic tissue injury. Accordingly, 
the modulation of the immunological balance between Th17 cells 
and Tregs could be exploited to revert the pro-inflammatory intes-
tinal environment. Indeed, several studies have demonstrated 
that the re-tuning of the Th17/Treg balance could dampen down 
intestinal inflammation resulting in the re-establishment of intes-
tinal immune homeostasis (40, 51). For instance, all-trans reti-
noic acid (ATRA) downregulated pro-inflammatory responses in 
both murine and human colitis by shifting the Th17/Treg profile 
(51). In this study, the upregulation of Foxp3 post treatment with 
ATRA and elevated levels of regulatory cytokines including IL-10 
and TGF-β were associated with the downregulation of IL-17. 
Furthermore, metformin was able to attenuate IBD severity and 
reduce inflammation through the regulation of Il17 and Foxp3 
expression, demonstrating the importance of the Th17/Treg bal-
ance in the regulation of intestinal inflammation [Table 1; (40)]. 
Taken together, these data support the notion that the attenuation 
of chronic intestinal inflammation in IBD is achieved through the 
restoration of a fine balance between pro- and anti-inflammatory 
responses (40, 51–54).
Th17/TReG BALANCe iN MeTABOLiC 
DiSeASeS
The Th17/Treg balance has also been linked with the develop-
ment of obesity-associated diseases such as type 2 diabetes 
(T2D) [Table 2; (1, 4, 5, 7, 55–57)]. Immunologically, obesity is 
characterized by low-grade chronic inflammation with abnormal 
cytokine production and the activation of various inflammatory 
TABLe 1 | The T helper 17/regulatory T cell (Th17/Treg) balance in iBD and metabolic disease.
experimental model Th17/Treg Changes Samples Reference
iBD
Patients with active UC and CD Il17 expression ↗ CD3+ T cells from colonic mucosa (2)
Patients with UC and CD Il17 expression ↗ Mucosa (3)
Patients with active CD Il22 expression ↗ Inflamed colonic lesions (47)
Murine colitis Il22 expression ↗ Colon
Patients with CD IL-22 ↗ Plasma (48)
Murine colitis Il22 and Il17 expression ↗ Inflamed colon
IBD patients Th17 and Th1/Th17 cells ↗ Lamina propria (50)
Tregs ↘ Peripheral blood
IBD patients IL-17A, IL-21, IL-23 ↗ Inflamed mucosa (41)
TGF-β, IL-10, IL-33 ↘ Inflamed mucosa
Metabolic diseases
Obese individuals Tregs ↘ Omentum fat (4)
Obese mice Tregs ↘ Visceral adipose tissue (VAT)
Obese patients with T2D IL-17A, IL-17F, IL-21, IL-9 ↗ Culture supernatant from activated PBMCs (55)
Obese individuals Tregs ↘ Adipose tissue (58)
Th17 cells ↗ Peripheral blood
Obese individuals Tregs ↘ Adipose tissue (57)
Mice fed HFD Th17+ CD4+ T cells ↗ Spleen (56)
Mice fed HFD % Foxp3+ CD4+ T cells ↘ VAT (5)
ob/ob mice % Foxp3+ CD4+ T cells ↘
Mice immunized with ileum microbiota from mice fed HFD IL-17+ and Foxp3+ CD4+ T cells ↘ Intestine (1)
IBDs, inflammatory bowel diseases; UC, ulcerative colitis; CD, Crohn’s disease; IL, interleukin; Tregs, regulatory T-cells; TGF-β, transforming growth factor beta; T2D, type 2 
diabetes; PBMCs, peripheral blood mononuclear cells; HFD, high-fat diet; Foxp3, forkead box P3.
Red arrow pointing toward upper right: increased levels; black arrow pointing toward lower right: decreased levels.
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pathways, associated with adverse clinical outcomes including 
insulin resistance and T2D (58). In obesity, the polarization of a 
Th17 phenotype, especially in secondary lymphoid organs (e.g., 
spleen and lymph nodes), contributes to the development of other 
chronic inflammatory diseases, including experimental autoim-
mune encephalomyelitis (EAE) and asthma (58). Similarly, the 
severity of trinitrobenzenesulfonic acid-induced colitis in obese 
mice was found to be associated with Th17 expansion (58). Despite 
their pathogenic role in the initiation and maintenance of chronic 
inflammation, Th17  cells have also been implicated as critical 
players in the control of adipogenesis and glucose homeostasis in 
the context of obesity (19, 59). In a recent study, intestinal RORγt+ 
IL-17+ CD4+ T-cells were shown to participate in energy metabo-
lism in mice. Indeed, a reduction in the numbers of RORγt+ and 
IL-17-producing CD4+ T-cells contributed to the development 
of insulin resistance (1). This observation supported the role of 
the intestinal Th17 lineage in the control of insulin sensitivity, an 
effect that differed from peripheral Th17 cells. Obesity also affects 
the numbers of Tregs and function in the regulation of whole-
body metabolism. Several studies have demonstrated that visceral 
adipose tissues (VATs) of lean mice are highly enriched with a 
unique population of Foxp3+ CD4+ Tregs that possess a distinct 
T-cell receptor repertoire, pattern of chemokine and chemokine 
receptor expression, and gene expression profile compared to 
other tissues (4–7). Under obese conditions, the abundance of 
these VAT-resident Tregs is markedly reduced. Several studies 
have suggested that this depletion of Tregs plays a role in the 
inflammatory process that may contribute to obesity-associated 
diseases such as T2D (4–7). Foxp3+ VAT-resident Tregs express 
unusually high levels of the peroxisome proliferator-activator 
receptor (PPAR)-γ (6), a key nuclear receptor controlling 
adipo genesis that is also a target of the insulin-sensitizing drug 
thia zolidinediones (60). The functional importance of PPAR-γ 
expression for VAT-resident Tregs was further reinforced by 
the observation that Treg-specific deletion of PPAR-γ leads to 
a significant reduction in the number of Tregs in VAT, but not 
in other tissues (6). Collectively, these data highlight the role of 
PPAR-γ-expressing Foxp3+ Tregs in the control of inflammation 
induced by obesity and in metabolic diseases such as T2D (6).
ePiGeNeTiC ReGULATiON OF THe Th17/
TReG BALANCe
The differentiation of Th17  cells and Tregs from naïve CD4+ 
T-cells is not only controlled by a combination of their cytokine 
milieu and transcriptional activities but is also subjected to 
epigenetic control through various mechanisms including DNA 
methylation (10, 61–63), changes in microRNA (miRNA) expres-
sion (64–69), and histone modification (22, 70–74), illustrating 
the complexity of CD4+ T-cell lineage decisions (Figure 1).
It has been proposed that the induction, maintenance, and 
function of Foxp3 are regulated by epigenetic mechanisms (9, 10, 
75). A seminal study revealed the complete demethylation in a 
region within the evolutionally conserved non-coding sequence 
elements of the Foxp3 gene and termed this region as the Treg-
specific demethylation region (TSDR) (61). It was reported that 
demethylated TSDR is strongly associated with the stable expres-
sion of Foxp3 in Tregs (61) and germ-line deletion of the TSDR 
resulted in the loss of Foxp3 expression (10). However, there is 
evidence suggesting that TSDR demethylation is not an on or off 
switch but instead determines the stability of Foxp3 expression 
(61–63). Interestingly, demethylation of the TSDR with DNA 
TABLe 2 | Changes in gut microbiota in iBD and metabolic diseases.
experimental model Microbiota involved Changes Samples Reference
iBD




Proteobacteria ↗ Small intestine
Firmicutes, Bacillus ↘
Patients with UC and CD Enterobacteriaceae ↘ Colon (85)
Bacteroidetes ↘











Patients with UC Roseburia hominis ↘ Fecal samples (88)
Faecalibacterium prausnitzii ↘
SCFAs ↘





Patients with UC Proteobacteria Unchanged Patients with UC
Bacteroidetes Unchanged
Clostridia Unchanged
Patients with CD Enterobacteriaceae ↗ Fecal samples (86)
Coccoides ↘
Metabolic diseases
Obese individuals Bacteroidetes ↘ Fecal samples (109)
Firmicutes ↗
Actinobacteria ↗
Obese individuals Bacteroidetes ↘ Fecal samples (108)
Firmicutes ↗




Patients with T2D Firmicutes ↘ Fecal samples (112)
Clostridia ↘
Betaproteobacteria ↗
ob/ob mice Bacteroidetes ↘ Cecal samples (106)
Firmicutes ↗
Firmicutes/Bacteroidetes ↗
HFD fed mice Bacteroides MIB ↘ Cecal samples (114)
E. rectale–C. coccoides ↘
Bifidobacterium spp. ↘
Enterobacteriaceae ↘
IBD, inflammatory bowel diseases; UC, ulcerative colitis; CD, Crohn’s disease; T2D, type 2 diabetes; HFD, high-fat diet.
Red arrow pointing toward upper right: increased levels; black arrow pointing toward lower right: decreased levels.
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demethylating compounds is associated with enhanced immu-
nosuppressive function of Foxp3+ Tregs and prevents the occur-
rence of diabetes in mice (75). Collectively, these data established 
that the demethylated TSDR contributes to the stable expression 
of Foxp3 in Tregs.
microRNAs are emerging as critical regulators of Th17 and 
Treg cell differentiation and function and consequently are also 
implicated in a number of diseases including IBD, diabetes, 
neurological diseases, and cardiovascular diseases (64, 65). 
Several studies have demonstrated that miR-155 is a prominent 
regulator of both Th17 and Treg differentiation and function 
in vitro and in vivo (64–69). For instance, miR155 is required for 
Treg development as miR-155-deficient (miR-155−/−) mice show 
a marked decrease in the frequency and absolute numbers of 
Tregs in both the thymus and secondary lymphoid organs (68). 
Despite a reduced number of Tregs, miR-155 is dispensable for 
Treg immunosuppressive function. This was confirmed by the 
finding that miR-155−/− mice did not spontaneously develop GI 
diseases, as seen in patients with IBD. Moreover, Tregs from miR-
155−/− mice retained the capacity to prevent colitis induced by the 
6Luo et al. Microbiota and Epigenetics of Th17/Treg
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 417
adoptive transfer of CD4+ CD45RBhigh T-cells into lymphopenic 
hosts (68). The above findings were not only recapitulated, but 
miR-155 was also found to be crucial in directing Th17 differen-
tiation and enhancing IL-17A secretion by Th17 cells by directly 
inhibiting the SOCS1 (suppressor of cytokines signaling) signal-
ing pathway (66). It also positively regulates Th17 cell function, 
but not that of Tregs (66). Together, these studies revealed that 
miR-155 is a critical driver of both Th17 and Treg development. 
Other miRNAs have also been reported to control Th17 and Treg 
development and function. For example, miR-182, miR-10a, and 
miR-17-92 are key regulators of Treg specification, stability, and 
their suppressor function in infectious and autoimmune diseases 
(76–78). miR-21 promotes Th17 differentiation and mediates the 
development of EAE as shown by the association between the 
defect in Th17 differentiation and the strong resistance to EAE in 
miR-21-deficient mice (79). In addition, anti-miR-21 treatments 
drastically reduced Th17 cell numbers as well as the severity of 
EAE (79). Likewise, miR-326 also drives the differentiation as well 
as migration of Th17 cells to inflammatory sites and the produc-
tion of IL-17A which all potentiate the development of EAE (80).
Evidence from genome-wide epigenetic analysis of Th17 cells 
uncovered the enrichment of active histone modifications such 
as histone H3 acetylation and trimethyl-histone H3 lysine 4 
(H3K4me3) in the promoters of cytokine and lineage-specific 
genes such as IL17a, IL17f, IL21, IL23R, and RORγt (22, 70–72). This 
suggests histone modifications such as acetylation or methylation 
play a role in Th17 cell lineage commitment (22). Similarly, pro-
moters of Treg-related genes, such as Foxp3, are also marked with 
the permissive H3K4me3 modification, which correlates strongly 
with gene expression (72). Furthermore, DNA demethylation 
of the TSDR was reported to correlate with increased levels of 
H3K4me3, suggesting that specific DNA demethylation and 
histone modifications have similar roles in the determination 
and commitment of the Treg lineage (73, 74). More recently, 
two histone acetyltransferases, CREB-binding protein (CBP) 
and p300, have been shown to control Treg suppressive function 
and stability (81). A combined Treg-specific deletion of CBP and 
p300 led to rapid development of fatal autoimmunity in mice 
within 3–4 weeks of birth. This was accompanied by decreased 
expression of genes characteristic of the Treg lineage, presence of 
autoantibodies, and increased infiltration of mononuclear cells in 
multiple organs (81), which resembles the clinical phenotype of 
scurfy or other Foxp3 mutant mice (82). Supporting the observa-
tion that Tregs are prone to lose Foxp3 expression in inflammatory 
diseases, CBP, and p300 act on the TSDR to control Treg stability 
and function during inflammation (81). These findings not only 
provide insight into the importance of histone acetyltransferases 
in the regulation of Treg development and function but also delin-
eate distinct roles for CBP and p300 in the control of Tregs (81).
DYSBiOSiS AND THe Th17/TReG 
BALANCe iN iBD AND MeTABOLiC 
DiSeASeS
As illustrated above, the Th17/Treg balance plays a critical role 
in control of the inflammatory process in IBD (38, 39). Although 
the exact etiology of IBD remains elusive, it is well accepted that 
this group of diseases preferentially affects genetically susceptible 
individuals and could result from a disproportionate activation 
of the immune system in response to changes affecting the gut 
microbiota [Tables 1 and 2; (44)]. Indeed, IBD is characterized by 
significant disturbances in the gut microbiota (83) and alterations 
in the balance between the dominant bacterial groups, depletion 
of particular bacteria, as well as a reduction in the diversity of 
the gut microbiota (84–86). A seminal study in the field recently 
identified that European children, considered to be at increased 
risk of IBD, were characterized by a reduced diversity in their gut 
microbiota and a total depletion of bacteria responsible for the 
digestion of dietary fibers when compared to their African coun-
terparts (87). In this particular study, striking differences were 
observed in the diet these two groups of children were exposed to, 
highlighting the importance of nutritional habits in the mainte-
nance of a healthy gut microbiota and the dramatic consequences 
of unfavorable dietary habits. Consistent with this observation, 
several studies have reported dramatic alterations in the propor-
tion of different groups of bacteria in the context of IBD. A relative 
depletion of members of Bacteroidetes and Lachnospiraceae (84) 
or a decrease in Roseburia hominis and Faecalibacterium praus­
nitzii (88) has been observed in patients diagnosed with CD or 
UC. However, contradictory results have also been observed, with 
patients with IBD showing an increase in both Proteobacteria and 
Bacteroidetes (89) or in Enterobacteriaceae (86). This discrepancy 
could be the result of the variability in the type of biological 
samples being investigated, ranging from biopsy samples to fecal 
samples, or even the sites where such biopsies are taken from in 
the GI tract [Table 2; (90)]. Despite the inherent challenges of 
identifying key groups of bacteria that contribute to the develop-
ment of IBD, dysbiosis is thought to be heavily involved in the 
pathophysiology of the disease. In particular, the ensuing immune 
activation and the establishment of chronic inflammation in the 
GI tract represent key steps in the development of IBD. Clear 
associations have now been established between the microbiota 
and T-cell differentiation or polarization and could thus link 
dysbiosis to changes affecting the Th17/Treg balance in IBD (91). 
The contribution of both dysbiosis and immune disturbance to 
IBD is further supported by the efficacy of anti-inflammatory, 
immunosuppressant, and immunomodulatory drugs, as well 
as microbiome modulators in the therapeutic arsenal for IBD 
(92, 93). In recent years, there has been a growing interest in the 
use of probiotics and prebiotics to treat or manage IBD, through 
the correction of intestinal dysbiosis (93). However, conflicting 
results have been reported regarding the use of probiotics or prebi-
otics to treat IBD, and both their efficacy and safety still remain to 
be established. For instance, promising results have been reported 
regarding the use of the probiotic, Escherichia coli Nissle 1917, to 
maintain remission in UC (94, 95). However, evidences support-
ing its use in the context of CD are still lacking (96). Some studies 
even reported that probiotics could cause harm (93). Similarly, if 
the beneficial effects of prebiotics in CD and UC remain elusive, 
some randomized studies using placebo as control have shown 
an improvement in GI symptoms and side effects following 
prebiotics supplementation in CD (97, 98). Another approach 
that has received much attention is the therapeutic manipulation 
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of the intestinal microbiota via fecal microbial transplantation 
(FMT) to restore symbiosis in IBD patients (99). If some studies 
have reported results that could suggest some potential benefits 
of FMT in UC (100, 101), significant concerns remain regarding 
safety. In particular, screening systems to identify the nature of 
the stool that is likely to be safe for donation and might provide 
some benefits are still lacking. Indeed, adverse effects of trans-
planting diseased fecal microbiota have been demonstrated (102). 
Impaired intestinal function, including increased intestinal bar-
rier dysfunction, faster GI transit, and innate immune activation, 
as well as exhibition of anxiety-like behavior, has been observed 
in mice that received fecal microbiota from patients with irritable 
bowel syndrome (102). These results suggest that the use of FMT 
as a management approach in IBD requires careful consideration 
and further research is warranted to establish its safety.
If chronic inflammation and alterations of the Th17/Treg bal-
ance are an integral component of IBD, a wide range of diseases 
increasingly recognized as comprising chronic inflammation, 
including obesity and T2D, may also be associated with such 
alterations. Reports supporting similarities in the physiopathol-
ogy of IBD and metabolic diseases have recently started to emerge 
and have identified dysbiosis as a common trait shared between 
these conditions (83, 103). Indeed, changes in the microbiota 
that accompany alterations in nutritional habits and the develop-
ment of obesity have been identified as critical contributors to 
the development of metabolic complications including insulin 
resistance and T2D and could even precede the establishment 
of local and systemic inflammation (83, 103, 104). Similar to 
what has been reported in IBD, both a decline in diversity and 
a remodeling of the bacterial component of the microbiota have 
been observed in the early stages of the development of obesity 
and insulin resistance (105). In mice, obesity has been linked to 
a decrease in Bacteroidetes and an increase in Firmicutes, as well 
as an increase in the Firmicutes/Bacteroidetes ratio (106). Similar 
changes have also been observed in mice fed a Western diet and 
these alterations could even be transmitted to germ-free mice by 
colonization using fecal microbiota obtained from obese mice 
(107). These alterations in the gut microbiota in response to obe-
sity have since been confirmed in obese individuals or patients 
with T2D (108–110), although conflicting results have also been 
reported (111, 112). It is noteworthy that changes affecting the 
microbial flora associated with obesity and insulin resistance have 
also been shown to be reversible in response to treatment using 
prebiotics or probiotics (113, 114). Indeed, mice fed a high-fat 
diet (HFD) and supplemented with the prebiotic oligofructose 
showed increased Bifidobacterium spp., improved glucose metab-
olism, and reduced plasma and adipose tissue pro-inflammatory 
cytokines (114). Similarly, supplementing mice fed a HFD with 
the probiotic bacteria Lactobacillus paracasei ssp. paracasei F19 
significantly reduced fat accumulation (113). Such beneficial 
effects were further confirmed in a clinical trial where adults with 
obese tendencies, who received the probiotic Lactobacillus gasseri 
SBT2055, were characterized by improved body composition and 
in particular decreased visceral and subcutaneous fat (115). These 
changes in the adipose tissue were associated with a decreased 
expression of pro-inflammatory genes in obese mice (116). 
These alteration were mediated by the regulation of macrophage 
infiltration and their regulatory rather than inflammatory polari-
zation in the adipose tissue (117), confirming the effect of the gut 
microbiota on inflammation in metabolic diseases.
Although it is clear that a link exists between the gut microbiota 
and the immune system, this association is complex. While the 
gut microbiota can contribute to shaping or even to activating the 
immune system, the local immune environment can also remodel 
the gut microbiota (91, 118). In lean and healthy individuals, the 
gut microbiota and the intestinal immune system are in homeo-
stasis, preventing bacteria and bacterial products leaking from 
the gut lumen to the underlying mucosa. This is partly achieved 
through the secretion of immunoglobulin A and the production 
of mucin by goblet cells. In this context, an anti-inflammatory 
environment is maintained through the secretion of TGF-β, as 
well as IL-25 and IL-33 by intestinal epithelial cells (IECs), favor-
ing Tregs (119). In the face of dysbiosis, this fragile equilibrium is 
disrupted, which leads to immune activation. Both a reduction in 
microbiota diversity and an altered composition of the microbiota 
are associated with decreased mucin production and increased 
intestinal permeability. Increased translocation and exposure of the 
underlying mucosa to pathogenic bacteria and bacterial products 
trigger the activation of the inflammasome, and increases toll-like 
receptor (TLR) and NOD-like receptor signaling, resulting in 
the production of IL-1β, IL-6, IL-12, IL-18, and IL-23 (119). This 
pro-inflammatory milieu can lead to the activation of the adaptive 
immune system and shift the Th17/Treg balance. Although both 
the gut microbiota and the immune system are involved in the 
pathogenesis of IBD, it remains unclear which may be the initial 
disease trigger. As described above, dysbiosis can lead to both 
intestinal and systemic inflammation, but the immune system 
may also shape the gut microbiota (118). In the context of IBD 
where genetic susceptibility (e.g., genetic deficiency in TLR1) and/
or environmental factors (pathogens) are present, immune activa-
tion and the resulting inflammatory process could contribute to 
altering IECs function and affect their secretory pattern, resulting 
in a remodeling of the gut microbiota (120).
The relationship between the gut microbiota and the immune 
system, and in particular the Th17/Treg balance, is now well 
established. Although it remains unclear as to which may be driv-
ing inflammatory diseases characterized by dysbiosis, their tight 
interaction contributes to the vicious circle of chronic intestinal 
inflammation.
MiCROBiOTA-DeRiveD MeTABOLiTeS 
AND THe ReGULATiON OF Th17/TReG 
CeLLS
It has been clearly established that the commensal microbial com-
munity can influence the Th17/Treg balance, as supported by the 
remodeling of that balance in germ-free mice or in mice treated 
with antibiotics (121–124). Although the exact mechanisms are 
still unclear, factors and metabolites derived from the gut micro-
biota have received significant attention. Bacteroides fragilis has 
been reported to protect against experimental colitis through the 
release of polysaccharide A [PSA; (125)]. This anti-inflammatory 
effect was mediated by a decreased production of IL-17 by 
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immune cells in the intestine and through the promotion of 
CD4+ T-cells differentiation to IL-10-producing cells and Foxp3+ 
Tregs (126). Similarly, Bacteroides thetaiotaomicron has been 
reported to exert anti-inflammatory effects by regulating the 
nuclear-cytoplasmic shuttling of PPAR-γ in both epithelial and 
intestinal cell lines (127). Although the effect on T-cells was not 
tested in that study, considering the critical role played by PPAR-γ 
in the differentiation of Treg, these findings confirm that the gut 
microbiota has a strong potential to influence the T-cell landscape 
in the GI tract. Metabolites produced by commensal microbes, 
and in particular short-chain fatty acids (SCFAs) including 
acetate, propionate, and butyrate, also play a critical role in 
mediating the effect of the gut microbiota on Treg induction 
both in the intestine and the colon (128–130). While SCFAs levels 
have been correlated with the number of colonic Tregs, butyrate 
in particular can support Treg differentiation both in vitro and 
in vivo (129). Such effects are not confined to the GI tract, and 
both butyrate and propionate have been reported to influence 
peripheral Treg development (128).
Several mechanisms potentially involved in SCFAs regulation 
of T-cell differentiation have been suggested, including the control 
of cellular metabolism or G-protein-coupled receptor (GPCR) 
signaling (131). Indeed, through their integration in the Krebs 
cycle as Acetyl-CoA, SCFAs can directly affect the cellular energy 
status and the ATP/ADP levels. This in turn leads to the activation 
of the mammalian target of rapamycin (mTOR), a critical kinase 
involved in T-cell differentiation, and can facilitate T effector or 
Treg differentiation (121, 132). In addition, both butyrate and 
propionate have been reported to inhibit de novo fatty acid syn-
thesis though the deactivation of acetyl-CoA carboxylase 1 (133), 
a process known to limit Th17 cell differentiation and promote 
Treg development (134). GPCRs, some of which act as receptors 
for various SCFAs including acetate, butyrate, propionate, or for 
niacin, have been linked to the regulation of inflammation in 
various diseases (135), and GPCR signaling plays a critical role in 
the regulation of Th17 cell and Treg development (131). Indeed, 
propionate has been reported to increase colonic Treg numbers, 
an effect thought to be GPR43 dependent (130). Proprionate also 
increases GPR15 levels, a homing receptor on colonic Tregs known 
to contribute to limiting inflammation (130, 136). Both butyrate 
and niacin have been shown to exert their anti-inflammatory 
effect by regulating colonic macrophages and dendritic cells in a 
GPR109A-dependent manner (135). In this report, colonic mac-
rophages and dendritic cells from Niacr1−/− (the gene encoding 
for GPR109A) mice failed to promote the differentiation of naïve 
CD4+ T-cells into Tregs and IL-10-producing T-cells. However, 
the effect of SCFAs on T-cell differentiation has been recently 
reported to be GPR41 and GPR43 independent, suggesting that 
additional mechanisms might play a role in that process (137).
ePiGeNeTiC ReGULATiON OF THe Th17/
TReG BALANCe BY THe GUT 
MiCROBiOTA
The inhibitory action of SCFAs on histone deacetylase (HDAC) 
activity suggests that the gut microbiota could contribute to 
shaping the host epigenome. This is supported by the recently 
emerging evidence linking dysbiosis to epigenetic changes in the 
GI tract, the adipose tissue, or the liver. Such changes have even 
been suggested to play a role in the development of pathological 
conditions including obesity and GI cancer (8, 138). The effect 
of SCFAs on T-cell differentiation could thus be mediated by 
reshaping the T-cell epigenome (Figure  2). In agreement with 
this, the effect of butyrate on Treg differentiation is thought 
to be linked to increased histone H3 acetylation in the Foxp3 
locus (129). Indeed, increased peripheral Treg differentiation in 
response to butyrate is mediated through increased acetylation 
of histone 3 at lysine 27 in the Foxp3 locus (128). In the same 
study, propionate potentiated peripheral Treg generation through 
the same HDAC inhibitory effect, while acetate failed to produce 
such action. The effect of propionate on HDAC inhibition has 
since been shown to specifically affect HDAC6 and HDAC9 and 
to be GPR43 dependent (130). Propionate increased not only the 
frequency and number of colonic Tregs but also their suppressive 
capacity, potentially through the increased expression of Foxp3 
and Il10, and reduced intestinal inflammation. However, it must 
be noted that both GPR41 and GPR43 have been recently sug-
gested to be dispensable for the inhibition of HDACs by SCFAs 
in T-cells (137). In this particular study, acetate, propionate, and 
butyrate were shown to present similar HDAC inhibitory effects 
and to regulate the mTOR pathway, affecting T-cell differentia-
tion in a cytokine milieu-dependent manner. Although the exact 
role of GPCRs in SCFA-induced HDAC inhibition still remains 
to be clarified, there is no doubt that SCFAs play a key role in 
T-cell differentiation by altering the T-cell epigenome. Several 
inflammatory diseases have been linked to epigenetic changes 
that could affect the Th17/Treg balance. In a murine model of 
colitis, the methyltransferase G9A has been identified as playing 
a key role in T-cell differentiation, in particular by facilitating 
dimethylation of histone H3 at lysine 9, supporting Th17 cell and 
Treg differentiation both in vivo and in vitro (18). A significant 
hypomethylation on MIR21 and increased expression of MIR21 
mRNA has recently been reported in circulating leukocytes from 
patients diagnosed with CD (139). This could have important 
consequences on the T-cell profile in these patients as miR-21 has 
been linked to Th17 cell differentiation (64, 79). The gut micro-
biota has been shown to downregulate miR-10a in the intestine 
and dendritic cells in specific pathogen-free mice (140). In this 
model, miR-10a downregulation was associated with increased 
expression of IL-12/IL23p40 in dendritic cells. These changes 
could affect the regulation of intestinal inflammation, as IL-12/
IL23p40 play a key role in Th1/Th17  cell differentiation (141). 
One of the potential mechanisms by which commensal bacteria 
could influence miRNA expression is through SCFAs. Butyrate 
has been reported to affect the expression of 44 different miRNAs 
in a human colon cancer cell line, and in particular members of 
the miR-106b family (142). These miRNAs included miR-17, a 
member of the miR-17-92 cluster which is known to promote 
Th17-mediated inflammation (143). The same miR cluster has 
further been reported to be critical for the differentiation of Treg, 
with the loss of miR-17-92 significantly affecting the accumulation 
of activated Tregs and their differentiation into IL-10-producing 
cells (76).
FiGURe 2 | epigenetic regulation of the T helper 17/regulatory T cell (Th17/Treg) balance by the gut microbiota. (A) Metabolites derived from the gut 
microbiota affect the T-cell epigenome influencing the Th17/Treg balance in the gastrointestinal (GI) tract. SCFAs including propionate, butyrate, and acetate which 
are mostly produced by clostridial clusters VIV and IV exert HDAC inhibitory activity, thereby increasing Foxp3 and Il10 expression and promoting Treg differentiation 
and function. SCFAs can also affect dendritic cells and macrophages, thereby inducing IL-10 and RA production and promoting Treg differentiation. PSA derived 
from Bacteroides fragilis contributes to increased expression of Il10 and Foxp3 in T-cell and reduces Il17 expression. Both Bifidobacterium and Lactobacillus 
contribute to the production of the methyl donor folate potentially influencing the methylome in T-cells. (B) Effect of microbiota-derived metabolites on the 
epigenome of peripheral T-cells. Similar to the GI tract, SCFAs increase Foxp3 and Il10 expression in peripheral T-cells through HDAC inhibition favoring Treg 
differentiation. Through unknown mechanisms, the gut microbiota increases the expression of MIR21 and the levels of miR-10a, potentially promoting Th17 
differentiation. SCFAs, short-chain fatty acids; PSA, polysaccharide A; HDAC, histone deacetylase; H3, histone 3; Foxp3, forkhead box P3; Il10, interleukin 10; 
RA, retinoic acid; Treg, regulatory T cell.
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FUTURe PeRSPeCTiveS AND 
CONCLUSiON
Changes in the gut microbiota are intimately linked to signifi-
cant alterations in Th17/Treg balance, potentially mediated by 
epigenetic mechanisms, and contributing to the development 
and establishment of IBD, obesity, and T2D, and possibly other 
chronic inflammatory conditions. Targeting such epigenetic 
changes through the use of HDAC inhibitors and miRNA-based 
therapies has recently started to emerge as a novel therapeutic 
option in the context of inflammatory diseases (144). This 
raises the question whether manipulating the gut microbiota 
could provide a novel approach to reshape the T-cell epigenome 
and influence the Th17/Treg balance in inflammatory diseases 
(Figure  2B). Several dietary interventions targeting the gut 
microbiome have reported positive outcomes in both animal 
models and human cohorts in IBD, obesity, or T2D (114, 116, 117, 
122, 145). Perhaps, some of the most promising dietary inter-
ventions include the use of prebiotics and probiotics. Prebiotics 
are defined as fermented ingredients capable of stimulating 
bacterial growth and activity in the GI microbiota providing 
health benefits to the host and include oligosaccharides that 
are non-digestible, poorly digested carbohydrates and dietary 
fibers. Supplementation with prebiotics can increase the rep-
resentation of butyrogenic strains in the gut microbiota, thus 
supporting an increased production of SCFAs. Increased levels 
of SCFAs could remodel the T-cell epigenome, favoring Treg 
differentiation (128–130), in line with the anti-inflammatory 
effect of SCFAs (129, 130). Even direct oral administration of 
SCFAs, and in particular butyrate, successfully remodeled the 
T-cell profile and improved inflammation in mice models of 
colitis (129, 146). Probiotics are live organisms which, when 
administered to the host, provide beneficial health effects. They 
represent an alternative option to prebiotics in modulating the 
gut microbiota and leading to positive immune adaptations 
in inflammatory diseases (116, 117). Several microorganisms 
presenting beneficial immunomodulatory properties that could 
help protect the host and provide novel therapeutic options for 
chronic inflammatory disorders have been identified (125, 147). 
B. fragilis, through the expression of PSA, is critical for the 
suppression of IL-17 production and the protection against 
inflammation (125). Bifidobacterium alone or in combination 
with prebiotics favors the production of the methyl donor folate 
(148), which may contribute to Treg survival through epigenetic 
mechanisms (149), in addition to its well-documented role in 
health and diseases prevention (150, 151). Similarly, probiotics 
(Bifidobacterium and Lactobacillus species) contained in mater-
nal milk have even been suggested to mediate some of the effects 
of breastfeeding on Treg differentiation (152). These observations 
highlight the importance of the specific components of the gut 
microbiota in the establishment and the maintenance of immune 
homeostasis. Alternatively, untested combinations of bacterial 
species may produce maximized responses.
Although there is still limited information on the direct 
effect of microbiota-based therapies on epigenetic regulation 
of the Th17/Treg balance, the continuously growing literature 
focusing on such interventions should soon provide the much 
needed evidence to guide future therapeutic strategies against the 
inflammatory component of IBD, obesity, or T2D. The system-
atic investigation of the effect of prebiotics or probiotics on the 
T-cell epigenome could provide invaluable information on their 
potential as immunomodulatory therapeutics and support the 
refining of such interventions. Modulation of the epigenome at 
gene specific loci, for example, using methyltransferases or acetyl-
transferases fused to a nuclease-null CRISPR-Cas9 could be used 
to improve the specificity of such therapies. In the face of the ever-
growing pandemic of inflammatory diseases, we are indeed in 
urgent need of innovative strategies that could specifically target 
the immune system while also affecting additional contributors 
to altered immune homeostasis. Challenges that still remain to 
be overcome include the identification of prebiotics, probiotics, 
or related metabolites with the highest potential to promote a bal-
anced immune system and the best modalities of administration, 
as well as the translation of such findings in the context of human 
diseases. Achieving these outcomes will undoubtedly place us in 
a better position to tackle inflammatory diseases.
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